We are delighted to join force with CrownBio, there is definitely a synergy between IIBR’s expertise in disease biology and CrownBio’s capability in translational research as well as operational know-how stated Dr. Hansen.
Santa Clara, CA (PRWEB) September 28, 2011
Crown Bioscience Inc. announced today that it has acquired The International Institute of BioMedical Research (IIBR), the world’s premier service provider for drug discovery in metabolic disease with its unique collection of fully characterized, non-human primate models with naturally occurring diabetes and metabolic syndrome. Dr. Barbara Hansen, founder of IIBR, will join Crown Bioscience as a Scientific Advisor for Metabolic Diseases. The acquisition expands Crown Bioscience’s in vivo research model platforms into metabolic diseases and further strengthens its leadership position in translational medicine and biotechnology.
Dr. Barbara C. Hansen, Director of the Center for Preclinical Research, and Professor of Internal Medicine and Pediatrics at the University of South Florida Tampa, is the leading expert in non-human primate models of obesity, diabetes, and associated metabolic syndromes. With over 30 years of research, Dr. Hansen has demonstrated that metabolic syndromes in non-human primate models are highly translatable to human disease in terms of disease natural history, mechanism and drug responses. This creates a unique opportunity for new target discovery, target validation, and drug evaluation in a highly predictable model system. With IIBR’s diabetic rhesus macaque and CrownBio’s diabetic cynomolgus monkeys, the combination will create a powerhouse for translational research in diabetes and metabolic syndrome.
“We are delighted to join force with CrownBio, there is definitely a synergy between IIBR’s expertise in disease biology and CrownBio’s capability in translational research as well as operational know-how,” commented Dr. Hansen. With 285 million patients today and 500 million by 2030 worldwide, diabetes has reached pandemic proportion. There is a growing and unmet need for new treatment for the disease and associated complications. “Unfortunately most of our knowledge and drug development programs still depend heavily on rodent models, which have been shown to be poorly predictive of human disease and drug response,” commented Dr. Yiyou Chen, Chief Scientific Officer of Crown Bioscience, “this contributes to the high rate of clinical failure for anti-diabetes drug development programs. With a critical mass of non-human primate models, we hope to enable our partners to discover new biological pathways and new treatments for this important disease.”
IIBR is a diabetes research service company founded by world’s leading expert in primate diabetes research, Dr. Barbara Hansen. Based on over 30 years’ research from Dr. Hansen’s laboratory, the company has been providing drug discovery services to many of the leading biotech pharmaceutical companies engaged in drug development for diabetes.
About Crown Bioscience, Inc.
Crown Bioscience, Inc. is a leading biotechnology company that provides its global biopharmaceutical industry partners with innovative and integrated solutions. Leveraging on its proprietary technology platforms in structure-based drug design and translational medicine, the company pioneers a business model that addresses the critical need of the pharmaceutical industry to improve R&D productivity while minimizing risks and retaining upside. Since its inception, CrownBio has been providing value-added services to help partners to identify the most promising compounds for clinical testing, and more importantly, enable its partners to develop strategies for biomarker development and patient stratification, an effort central to developing personalized therapeutics.
As a leading drug discovery partner, the company has established strategic partnerships in the oncology field with Pfizer and other large global pharmaceutical companies and leading Chinese pharmaceutical firms. The mandate of these partnerships is to deliver clinical candidates with well-defined clinical development path. By deploying its full capabilities across key functional disciplines in target validation, protein engineering, fragment-based drug design, medicinal/computational chemistry, formulation, DMPK, quantitative biology, pharmacology, and biomarker discovery, the company functions as a highly efficient external drug discovery engine to complement its partners' internal drug R&D effort. It is actively working with other biotech and pharmaceutical companies to establish similar partnerships in oncology and metabolic syndrome.
For more information:
Please visit our web site at http://www.crownbio.com
Laura Sailor – lsailor(at)crownbio(dot)com
+1 606 686 9330